Possible Involvement of Toll-Like Receptors in the Pathogenesis of Myasthenia Gravis
- 396 Downloads
Toll-like receptors (TLRs), the innate immunity components, have been demonstrated to participate in multiple autoimmune diseases. However, our knowledge of the roles of TLRs in myasthenia gravis (MG) is still scarce. In this study, we detected the mRNA expression of TLR1 to TLR10 in peripheral blood mononuclear cells (PBMCs) of MG patients and the healthy controls by quantitative real-time polymerase transcription chain reaction. Our data demonstrate that aberrant expressions of TLRs exist in the PBMCs of MG patients and of the total, expression level of TLR9 mRNA has significantly positive relation with the clinical severity of MG, which suggests that TLRs may be involved in the pathogenesis of MG.
KEY WORDSmyasthenia gravis Toll-like receptors innate immunity
This work was supported by the National Natural Science Foundation of China (30971033).
Conflict of Interest
The authors declare no competing financial interests.
- 6.Takeda, K. and S. Akira. 2007. Toll-like receptors. Current Protocols in Immunology. Chapter 14: Unit 14 12.Google Scholar
- 9.Devaraj, S., M.R. Dasu, J. Rockwood, W. Winter, S.C. Griffen, and I. Jialal. 2008. Increased Toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. The Journal of Clinical Endocrinology and Metabolism 93: 578–583.PubMedCrossRefGoogle Scholar
- 15.Bernasconi, P., M. Barberis, F. Baggi, L. Passerini, M. Cannone, E. Arnoldi, L. Novellino, F. Cornelio, and R. Mantegazza. 2005. Increased Toll-like receptor 4 expression in thymus of myasthenic patients with thymitis and thymic involution. The American Journal of Pathology 167: 129–139.PubMedCrossRefGoogle Scholar
- 17.Jaretzki 3rd, A., R.J. Barohn, R.M. Ernstoff, H.J. Kaminski, J.C. Keesey, A.S. Penn, and D.B. Sanders. 2000. Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology 55: 16–23.PubMedCrossRefGoogle Scholar
- 18.Osserman, K.E., and G. Genkins. 1971. Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. The Mount Sinai Journal of Medicine 38: 497–537.Google Scholar
- 19.Sharshar, T., S. Chevret, M. Mazighi, P. Chillet, G. Huberfeld, C. Berreotta, M. Houfani, and P. Gajdos. 2000. Validity and reliability of two muscle strength scores commonly used as endpoints in assessing treatment of myasthenia gravis. Journal of Neurology 247: 286–290.PubMedCrossRefGoogle Scholar
- 22.Roelofs, M.F., M.H. Wenink, F. Brentano, S. Abdollahi-Roodsaz, B. Oppers-Walgreen, P. Barrera, P.L. van Riel, L.A. Joosten, D. Kyburz, W.B. van den Berg, and T.R. Radstake. 2009. Type I interferons might form the link between Toll-like receptor (TLR) 3/7 and TLR4-mediated synovial inflammation in rheumatoid arthritis (RA). Annals of the Rheumatic Diseases 68: 1486–1493.PubMedCrossRefGoogle Scholar